Erectile dysfunction (ED) affects an estimated 30 million men in the United States alone, with prevalence increasing with age. Despite the availability of effective oral therapies, many men do not achieve satisfactory results, highlighting the ongoing need to understand the underlying mechanisms of ED and to develop novel treatments. Physiological models—ranging from living animals to computer simulations—are indispensable tools for dissecting the complex interplay of vascular, neurological, endocrine, and psychological factors that govern penile erection. By replicating key aspects of human physiology, these models allow researchers to test hypotheses, evaluate drug safety and efficacy, and explore regenerative approaches that could one day restore natural erectile function. This article provides an in-depth look at the most common physiological models used in ED research, how they illuminate disease mechanisms, and how they guide the development of new therapies.

Understanding the Pathophysiology of Erectile Dysfunction

Before examining the models themselves, it is essential to understand the physiological processes that lead to a normal erection and how they can fail. Erection occurs when parasympathetic nerve signals trigger the release of nitric oxide (NO) from endothelial cells and non-adrenergic non-cholinergic (NANC) nerves. NO activates guanylyl cyclase in corpus cavernosum smooth muscle cells, increasing cyclic guanosine monophosphate (cGMP) levels. cGMP causes smooth muscle relaxation, allowing blood to flow into the sinusoidal spaces, compressing subtunical venules and trapping blood to maintain rigidity. Detumescence results from cGMP degradation by phosphodiesterase type 5 (PDE5) and sympathetically mediated smooth muscle contraction.

ED can arise from disruptions at any point in this cascade. Vascular causes include atherosclerosis, hypertension, and diabetes, which impair endothelial function and NO production. Neurological causes include spinal cord injury, multiple sclerosis, and diabetic neuropathy. Hormonal imbalances such as low testosterone, hyperprolactinemia, or thyroid dysfunction also contribute. Additionally, psychological factors like anxiety and depression can amplify organic ED. Physiological models must capture these diverse inputs to be clinically relevant.

Key Physiological Models for Studying ED

Researchers classify models into three broad categories: in vivo (whole animal), in vitro (isolated tissues or cells), and computational (mathematical simulations). Each offers a different level of complexity and control.

In Vivo Animal Models

In vivo models remain the gold standard for studying erectile physiology in a systemic context. The most commonly used species are rats, mice, rabbits, and dogs. These models allow researchers to measure intracavernosal pressure (ICP) and mean arterial pressure (MAP) to calculate the ICP/MAP ratio, a reliable indicator of erectile function.

  • Rat models: Sprague-Dawley and Wistar rats are favored because of their low cost, ease of handling, and well-characterized anatomy. Common ED induction methods include bilateral cavernous nerve crush (to simulate nerve injury after prostatectomy), streptozotocin-induced diabetes (to model diabetic ED), and high-fat diet-induced obesity (to model metabolic syndrome). Researchers routinely use these models to test PDE5 inhibitors, gene therapy vectors, and stem cell injections.
  • Mouse models: Transgenic and knockout mice enable mechanistic studies at the molecular level. For example, eNOS (endothelial nitric oxide synthase) knockout mice exhibit impaired erection, confirming NO’s crucial role. Mouse models are also used to study aging-related ED and the effects of specific genes on cavernous smooth muscle function.
  • Rabbit models: Rabbits possess a corpus cavernosum that is anatomically and physiologically similar to humans, making them ideal for studying drug-induced relaxation and contraction in vitro. However, their use in chronic studies is limited by cost and housing requirements.
  • Canine models: Dogs have been used historically for nerve stimulation studies and testing of surgical techniques, but ethical concerns and expense have reduced their use in favor of rodents.

In vivo models are essential for evaluating the pharmacokinetics and systemic side effects of new treatments. They also allow researchers to study the effects of comorbidities like diabetes, hypertension, and hyperlipidemia on erectile function.

In Vitro Organ Bath and Cell Culture Models

In vitro models provide a controlled environment to examine specific cellular and tissue responses without the confounding variables of a living animal. The most common in vitro preparations are isolated corpus cavernosum strips and cultured smooth muscle or endothelial cells.

  • Organ bath studies: Strips of corpus cavernosum from rats, rabbits, or humans (obtained during penile prosthesis surgery) are mounted in tissue baths filled with physiological salt solution. Electrical field stimulation or drug administration measures contractile and relaxant responses. This system is ideal for screening new PDE5 inhibitors, evaluating Rho-kinase inhibitors, and studying the effects of oxidative stress on smooth muscle relaxation.
  • Cell culture models: Primary human cavernous smooth muscle cells or endothelial cells can be cultured and subjected to various stressors (high glucose, hypoxia, inflammatory cytokines) to mimic ED conditions. Researchers can then assay NO production, cGMP levels, and gene expression. These models are particularly useful for investigating molecular pathways like the NO/cGMP cascade, RhoA/Rho-kinase signaling, and the role of advanced glycation end products (AGEs) in diabetic ED.
  • Co-culture systems: More advanced in vitro setups combine smooth muscle cells and endothelial cells in a transwell or 3D matrix to simulate the interaction between these two cell types. This allows study of paracrine signaling and the effects of drugs on cell-cell communication.

While in vitro models offer high reproducibility and the ability to test many conditions simultaneously, they lack the systemic influences of blood flow, nerve input, and hormonal feedback. Therefore, results must be validated in vivo.

Computational and Mathematical Models

Computational models use mathematical equations to simulate the biomechanical and biochemical processes of erection. These models range from simple compartmental simulations of blood flow to complex finite element analyses of tissue deformation.

  • Hemodynamic models: These models represent the penis as a system of resistors and capacitors, predicting how changes in arterial inflow, venous outflow, and cavernous smooth muscle tone affect ICP. They can simulate the effects of different drugs or diseases on pressure profiles.
  • Molecular pathway models: Ordinary differential equations model the kinetics of NO synthesis, cGMP production, and PDE5 activity. Such models help predict how alterations in enzyme activity or substrate availability affect the duration and magnitude of erection.
  • Finite element models: These 3D models incorporate the geometry and material properties of the tunica albuginea and corpus cavernosum. They are used to study mechanical factors such as buckling during penetration or the effects of fibrosis on erectile rigidity.

Computational models are cost-effective and allow rapid screening of many scenarios. However, they require accurate parameter values from experimental data, and they cannot yet fully replicate the complex biological responses seen in living systems.

Applications of Models in Treatment Development

Physiological models have accelerated the development of every major ED therapy, from oral drugs to regenerative medicine. Below are key areas where models play a critical role.

Phosphodiesterase Type 5 (PDE5) Inhibitors

The development of sildenafil (Viagra) and its successors (tadalafil, vardenafil, avanafil) relied heavily on both in vitro and in vivo models. Early organ bath studies showed that sildenafil potentiated relaxation of rabbit corpus cavernosum strips in response to NO donors. Rat models confirmed that intravenous sildenafil increased ICP/MAP ratios following cavernous nerve stimulation. Computational models helped optimize dosing regimens by simulating drug concentration in the corpus cavernosum over time. Even today, when researchers develop new PDE5 inhibitors, they first test them in isolated tissue strips and then in diabetic or aged rats to assess efficacy in disease models.

Hormonal Therapies

Testosterone replacement therapy for hypogonadal ED was validated using castrated rat models, which exhibit reduced ICP responses that are reversed by testosterone administration. In vitro studies using human cavernous smooth muscle cells demonstrated that testosterone upregulates eNOS expression and NO production. These models continue to inform the optimal route, dose, and timing of testosterone therapy, as well as risk-benefit assessments for men with prostate cancer concerns.

Gene Therapy and Molecular Approaches

Gene therapy for ED aims to deliver genes encoding for NO synthase, growth factors, or ion channels to restore erectile function. Preclinical studies typically use rat models of cavernous nerve injury or diabetes. For example, adenoviral delivery of eNOS or nNOS (neuronal NOS) has been shown to improve ICP responses in aged or diabetic rats. In vitro cell cultures allow researchers to test transfection efficiency and safety before moving to animal experiments. Similarly, antisense oligonucleotides targeting Rho-kinase have been tested in rabbit corpus cavernosum strips and then in hypertensive rat models.

Stem Cell Therapy and Regenerative Medicine

Stem cell therapy is one of the most promising areas for treating ED that is refractory to PDE5 inhibitors, especially after radical prostatectomy. Animal models—primarily rats—are used to evaluate the efficacy of bone marrow-derived mesenchymal stem cells (BM-MSCs), adipose-derived stem cells (ADSCs), and urine-derived stem cells. These models involve injecting stem cells into the corpus cavernosum after nerve crush or diabetic induction, then measuring ICP/MAP improvement weeks later. Histological analysis shows that stem cells not only differentiate into endothelial and smooth muscle cells but also secrete paracrine factors that promote angiogenesis and nerve regeneration. A 2021 review in Stem Cells International summarizes key preclinical studies in rat models. Before moving to human trials, in vitro safety assays confirm that the cells do not form tumors or cause fibrosis.

Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)

Li-ESWT has emerged as a non-invasive treatment for ED, potentially by stimulating neovascularization and nerve regeneration. Its development relied heavily on animal models. In diabetic rat models, Li-ESWT increased the expression of VEGF, eNOS, and PCNA, and improved erectile function measured by ICP. A study in Prostate Cancer and Prostatic Diseases showed that Li-ESWT could also improve erectile recovery after nerve-sparing prostatectomy in rats. These findings justified early clinical trials, which have since shown variable but promising results.

Combination Therapies

Physiological models are increasingly used to test synergistic effects of combined treatments. For instance, combining PDE5 inhibitors with stem cells or Li-ESWT may yield greater improvement than either alone. In a rat model of diabetic ED, the combination of sildenafil and ADSCs showed enhanced recovery of ICP compared to monotherapy. Computational models can simulate the time course of such interactions to identify optimal dosing intervals.

Limitations of Current Physiological Models

While invaluable, physiological models have important limitations that must be considered when translating findings to human patients.

  • Species differences: Rodent models differ from humans in penile anatomy (e.g., the presence of a penile bone in rodents) and in some molecular pathways. A drug that works well in rats may not perform identically in humans due to differences in metabolism or receptor distribution.
  • Acute vs. chronic conditions: Many in vivo models induce ED through acute injury (e.g., nerve crush) that does not perfectly replicate the gradual, multifactorial progression of human ED from aging, diabetes, or cardiovascular disease.
  • In vitro oversimplification: Cell cultures lack the three-dimensional architecture and paracrine interactions of intact tissue. Organ bath studies remove systemic hormones and blood flow, so results may not reflect in vivo responses.
  • Computational model validation: Mathematical models depend on accurate parameter inputs. If experimental data are incomplete or biased, the model’s predictions can be misleading.
  • Ethical concerns: The use of live animals, especially dogs, raises ethical issues that have led to stricter regulations and the search for alternatives like advanced in vitro models.

Despite these limitations, physiological models remain the backbone of preclinical ED research. Advances in human tissue engineering and organ-on-a-chip technology may soon provide more accurate and ethical alternatives.

Future Directions: Next-Generation Models

Researchers are actively developing more sophisticated models that better mimic human physiology and disease. These include:

  • Humanized animal models: Immunodeficient mice injected with human stem cells or implanted with human penile tissue can be used to study human-specific responses to treatments.
  • 3D bioprinted corpus cavernosum: Using bioinks containing smooth muscle and endothelial cells, scientists have created small constructs that can contract and relax in response to drugs. These “organoids” may replace some animal tests.
  • Microfluidic “penis-on-a-chip” models: These devices mimic the blood flow and pressure dynamics of the corpus cavernosum on a microscale, allowing high-throughput drug screening with human cells.
  • Advanced computational models integrating genomics and proteomics data: Machine learning algorithms can now predict how individual patients will respond to specific ED treatments based on their genetic profile, ushering in the era of personalized medicine.

These innovations promise to accelerate the discovery of safer and more effective ED therapies while reducing reliance on animal testing.

Conclusion

Erectile dysfunction is a complex condition with vascular, neurological, endocrine, and psychological underpinnings. Physiological models—whether in vivo, in vitro, or computational—have been instrumental in unraveling the mechanisms of normal erection and the pathogenesis of ED. They have enabled the development of PDE5 inhibitors, hormonal therapies, and emerging regenerative treatments such as stem cell therapy and low-intensity shockwave therapy. While models have limitations, ongoing technological advances are producing more human-relevant and precise tools. As researchers continue to refine these models, they will bring us closer to truly personalized and curative treatments for the millions of men living with erectile dysfunction. For further reading on the current state of ED research, consult resources from the National Institute of Diabetes and Digestive and Kidney Diseases or recent reviews in PubMed.